30 January 2018 - - Toronto, Canada-based patent protected pharmaceutical developer Antibe Therapeutics Inc. (TSX Venture: ATE, OTCQX: ATBPF) has enrolled and begun treatment in the final subjects in the Phase 2B double-blind clinical trial of ATB-346, the company said.
The study is being conducted in 240 healthy volunteers and is designed to demonstrate the superiority of ATB-346 in gastrointestinal safety compared to naproxen.
ATB-346 is a hydrogen sulfide-releasing derivative of naproxen.
It is well-accepted that patients requiring treatment with NSAIDs would benefit greatly from an effective, GI-sparing anti-inflammatory/analgesic agent such as ATB-346.
Antibe develops safer medicines for pain and inflammation. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine.